Drug intelligence / Profile preview

Bioheart Acute Cell Therapy

Development stage: Preclinical
Lead developer: Bioheart
Modality: Stem Cell Therapies → Cell Therapies
Administration: Injection

Overview

Bioheart Acute Cell Therapy is an autologous, adipose tissue-derived stem cell treatment developed by Bioheart, Inc. for the treatment of acute heart damage, such as that resulting from a myocardial infarction. The therapy involves harvesting stem cells from the patient's own adipose (fat) tissue, which are then processed and delivered to the heart to promote the repair and regeneration of damaged cardiac tissue. This biologic therapy is distinct from Bioheart's lead candidate, MyoCell, which utilizes skeletal muscle-derived myoblasts for the treatment of chronic heart failure. Bioheart Acute Cell Therapy is specifically designed to address the immediate damage following acute cardiac events.

Brand names: Bioheart Acute Cell Therapy
Other names: Adipose-derived stem cell therapy for acute heart damage

Beyond the preview

Go deeper on Bioheart Acute Cell Therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioheart Acute Cell Therapy.

Explore the full profile